题名 | Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder |
作者 | |
发表日期 | 2018 |
发表期刊 | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Article |
关键词 | Solifenacin tamsulosin benign prostatic hyperplasia overactive bladder curative effect observation |
其他关键词 | URINARY-TRACT SYMPTOMS ; OXIDATIVE STRESS ; HYPERACTIVITY ; POPULATION ; INJECTION ; MODEL ; OAB |
摘要 | Objective: To observe the clinical efficacy of solifenacin combined with tamsulosin in benign prostatic hyperplasia (BPH) with overactive bladder (OAB). Methods: One hundred and six patients with BPH and OAB were enrolled in Department of Urology Surgery, Ruian City People's Hospital. The patients were divided into control group and study group (53 cases for each group). In the control group, tamsulosin was used alone for 12 weeks. In the study group, solifenacin was added on the basis of the control group method for 12 weeks. International prostate symptom score (IPSS), overactive bladder symptom scores (OABSS), urine storage period symptom score (USPSS), voiding symptom score (VSS), maximum urinary flow rate (Qmax), residual urine volume (RUV), total effective rate, quality of life index (QOL), urinary nerve growth factor, and adverse reactions were analyzed and compared. Results: The general data of the two groups were statistically insignificant and comparable (P > 0.05). After treatment, the patients in the study group were superior to those in the control group in IPSS, OABSS, USPSS, VSS, and Qmax indicators. And the results of two groups were statistically different (P < 0.05). There was no significant difference in the residual urine volume between the two groups (P > 0.05). In terms of total efficiency, the study group was superior to the control group with statistical differences (P < 0.05). In terms of quality of life scores, the two groups were significantly improved after treatment (P < 0.05), and the quality of life scores in the study group after treatment were significantly better than those in the control group (P < 0.05). In terms of urine nerve growth factor, the two groups of patients significantly improved after treatment (P < 0.05), and the study group was statistically superior to the control group (P < 0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The clinical efficacy of solifenacin combined with tamsulosin on benign prostatic hyperplasia combined with overactive bladder patients is better than that of tamsulosin alone and does not increase the incidence of side effects. It is worthy of clinical application. |
出版者 | E-CENTURY PUBLISHING CORP |
出版地 | MADISON |
ISSN | 1940-5901 |
卷号 | 11期号:12页码:13820-13826 |
页数 | 7 |
WOS类目 | Medicine, Research & Experimental |
WOS研究方向 | Research & Experimental Medicine |
WOS记录号 | WOS:000454547200116 |
收录类别 | SCIE |
通讯作者地址 | [Li, Jie]Ruian Peoples Hosp, Dept Pharm, 108 Wansong Rd, Ruian 325200, Zhejiang, Peoples R China. |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/15594 |
专题 | 第一临床医学院(信息与工程学院)、附属第一医院_药学部 |
通讯作者 | Li, Jie |
作者单位 | 1.Ruian Peoples Hosp, Dept Urol, Ruian, Zhejiang, Peoples R China; 2.Ruian Peoples Hosp, Dept Pharm, 108 Wansong Rd, Ruian 325200, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China |
推荐引用方式 GB/T 7714 | Chen, Siping,Wen, Huihuang,Zhou, Bin,et al. Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder[J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,2018,11(12):13820-13826. |
APA | Chen, Siping, Wen, Huihuang, Zhou, Bin, & Li, Jie. (2018). Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 11(12), 13820-13826. |
MLA | Chen, Siping,et al."Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder".INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE 11.12(2018):13820-13826. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论